Type 2 Diabetes Mellitus Clinical Trial
Official title:
WellStart Type 2 Diabetes Study
Verified date | February 2020 |
Source | Ohio University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, controlled comparison study that will evaluate the effectiveness of WellStart, a virtual intensive therapeutic lifestyle change program to control type 2 diabetes.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 1, 2018 |
Est. primary completion date | December 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Established diagnosis of type 2 diabetes (T2DM) - Between the ages of 18 and 65 years-old - Own and willing to use a smart phone or computer, and have daily internet access - Have an email account - Have access to resources (finances and transportation) that allow for regular acquisition (at least once weekly) of groceries, including produce - Access to resources that allow for food preparation at home (refrigeration, basic kitchen appliances and supplies) - Willingness to attempt changes in food preparation and consumption, and physical activity. -Scoring at least a 7/10 in both readiness for change and confidence of success; 1= not ready / no confidence; 10 = extremely ready / extremely confident of success - Exclusion Criteria: - Dementia - Advanced renal disease (stage 4 or 5) with or without hemodialysis - Congestive Heart Failure - Taking warfarin - Pregnancy or plans for pregnancy - Current smoker of tobacco cigarettes - Adults who have a physical limitation to prepare their own food or incorporate movement into their lifestyle (based on questionnaire answer) - Brittle diabetes and/or history of hospitalization for high or low blood sugar - Difficult-to-control hypertension and / or on 4 or more medications for high blood pressure. - Does not speak or understand English - Inability to use email or the Internet |
Country | Name | City | State |
---|---|---|---|
United States | Ohio University | Athens | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio University |
United States,
Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054. — View Citation
Esselstyn CB Jr. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). Am J Cardiol. 1999 Aug 1;84(3):339-41, A8. — View Citation
Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: JAMA 1999 Apr 21;281(15):1380. — View Citation
Song M, Fung TT, Hu FB, Willett WC, Longo VD, Chan AT, Giovannucci EL. Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality. JAMA Intern Med. 2016 Oct 1;176(10):1453-1463. doi: 10.1001/jamainternmed.2016.4182. Erratum in: JAMA Intern Med. 2016 Nov 1;176(11):1728. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hemoglobin A1c | glycosylated hemoglobin, measure of diabetes control over last 3 months | 6 months | |
Primary | Weight | risk factor for diabetes | 6 months | |
Secondary | Short Form Health Survey - 36 Questions (SF-36) | Survey of patient health status | 6 months | |
Secondary | Total cholesterol | risk factor for cardiovascular disease, a comorbidity of diabetes | 6 months | |
Secondary | Low density lipoprotein cholesterol (calculated) | risk factor for cardiovascular disease, a comorbidity of diabetes | 6 months | |
Secondary | High density lipoprotein cholesterol | risk factor for cardiovascular disease, a comorbidity of diabetes | 6 months | |
Secondary | Triglycerides | risk factor for cardiovascular disease, a comorbidity of diabetes | 6 months | |
Secondary | Systolic Blood Pressure | risk factor for cardiovascular disease, a comorbidity of diabetes | 6 months | |
Secondary | Diastolic Blood Pressure | risk factor for cardiovascular disease, a comorbidity of diabetes | 6 months | |
Secondary | Days per week of exercise | Average days per week of exercise, self reported by patient | 6 months | |
Secondary | Minutes per day of exercise | Average minutes per day of exercise, self reported by patient | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |